OneDigital Investment Advisors LLC Cuts Stake in Pfizer Inc. $PFE

OneDigital Investment Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 258,994 shares of the biopharmaceutical company’s stock after selling 24,712 shares during the period. OneDigital Investment Advisors LLC’s holdings in Pfizer were worth $6,237,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Plato Investment Management Ltd boosted its position in shares of Pfizer by 41.5% in the 2nd quarter. Plato Investment Management Ltd now owns 225,254 shares of the biopharmaceutical company’s stock worth $5,392,000 after purchasing an additional 66,017 shares in the last quarter. Cura Wealth Advisors LLC increased its position in Pfizer by 5.8% during the 2nd quarter. Cura Wealth Advisors LLC now owns 21,140 shares of the biopharmaceutical company’s stock valued at $509,000 after buying an additional 1,167 shares in the last quarter. Simplicity Wealth LLC raised its stake in Pfizer by 144.2% in the second quarter. Simplicity Wealth LLC now owns 109,120 shares of the biopharmaceutical company’s stock valued at $2,628,000 after buying an additional 64,440 shares during the last quarter. Wealth Effects LLC raised its stake in Pfizer by 2.6% in the second quarter. Wealth Effects LLC now owns 78,083 shares of the biopharmaceutical company’s stock valued at $1,880,000 after buying an additional 2,008 shares during the last quarter. Finally, Gould Asset Management LLC CA grew its stake in shares of Pfizer by 16.5% during the second quarter. Gould Asset Management LLC CA now owns 9,062 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 1,283 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.8%

Pfizer stock opened at $28.00 on Friday. The firm has a market cap of $159.59 billion, a PE ratio of 36.84 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The stock’s 50 day simple moving average is $25.30 and its two-hundred day simple moving average is $26.25. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $0.78 EPS. The business’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer’s payout ratio is presently 226.32%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Citigroup boosted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. Weiss Ratings cut Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday. Finally, Guggenheim decreased their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.